|
The Role of Self-Medication in Cost-Containment in the United StatesPublished by: Decision Resources Published: Apr. 6, 2005 The price of this report has been reduced due to its age. The original price was $1,900 for PDF E-mail From Publisher.Table of Contents
AbstractWith sales in 2003 estimated at $17.5 billion, the U.S. market for over-the-counter (OTC) drugs is by far the largest in the world, but it is arguably far from being the most dynamic self-medication market. The U.S. market's sluggish performance is attributable in part to the very cautious attitude of the FDA toward the reclassification of prescription drugs as nonprescription medicines, a process known as "Rx-to-OTC switching." However, recent statements made by the FDA indicate that its attitude toward Rx-to-OTC switching is about to change. We begin this report by considering the perspectives on self-medication of three major stakeholder groups: consumers, payers, and manufacturers, plus the position of the FDA. We then examine the cost-containment implications of Rx-to-OTC switching in two drug classes that have had recent switch approvals (nonsedating antihistamines and proton pump inhibitors) and two classes that may see switches in the near future (statins and obesity therapies). We conclude with a brief assessment of the outlook and implications for the pharmaceutical industry.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||